Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 6/20 | 0.39 |
| ▸ | KDM1B | Q8NB78 | 4/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA3 | P07451 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31633769 | 1.00 | KDM1A (0.39) | KDM1AKDM1BKCNH2NPC1RAB9A | |
| SCHEMBL1191944 | 0.89 | KDM1A (0.34) | KDM1AKDM1BKCNH2NPC1RAB9A | |
| SCHEMBL10122745 | 0.86 | KDM1A (0.31) | KDM1AKDM1BKCNH2CA1CA2 | |
| SCHEMBL31544453 | 0.83 | KDM1A (0.34) | KDM1AKDM1BKCNH2NPC1RAB9A | |
| SCHEMBL505780 | 0.82 | KDM1A (0.48) | KDM1AKDM1BKCNH2NPC1RAB9A | |
| SCHEMBL14129494 | 0.82 | CA1 (0.32) | CA1CA2CA3CA9 | |
| SCHEMBL29844001 | 0.80 | ACHE (0.32) | KDM1AKDM1BKCNH2CA1CA2 | |
| SCHEMBL21142526 | 0.80 | ACHE (0.32) | KDM1AKDM1BKCNH2CA1CA2 | |
| SCHEMBL21834387 | 0.77 | ALDH1A1 (0.35) | KDM1AKDM1BKCNH2CA1CA2 | |
| SCHEMBL22289792 | 0.77 | AHR (0.39) | KDM1AKDM1BNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120192780-A | Fluorine-containing benzene alkyne liquid crystal compound, preparation method and composition thereof | 西安近代化学研究所 | 2025-06-24 | — | — | CN | claimed |
| US-20260124309-A1 | STAT6 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| US-12590091-B2 | 1H-pyrrolo[3,2-C]pyridine and 1H-pyrrolo[2,3-C]pyridine derivatives as TLR9 inhibitors for the treatment of fibrosis | BRISTOL-MYERS SQUIBB COMPANY (US) | 2026-03-31 | — | — | US | disclosed |
| US-20260048035-A1 | MODULATORS OF TNF-ALPHA ACTIVITY | FORWARD THERAPEUTICS INC (US) | 2026-02-19 | — | — | US | disclosed |
| US-12521368-B2 | Modulators of TNF-alpha activity | FORWARD THERAPEUTICS, INC. (US) | 2026-01-13 | — | — | US | disclosed |
| US-20250345310-A1 | MODULATORS OF TNF-ALPHA ACTIVITY | FORWARD THERAPEUTICS INC (US) | 2025-11-13 | — | — | US | disclosed |
| US-20250333429-A1 | MODULATORS OF TNF-ALPHA ACTIVITY | FORWARD THERAPEUTICS INC (US) | 2025-10-30 | — | — | US | disclosed |
| EP-4622981-A1 | MODULATORS OF TNF-ALPHA ACTIVITY | Forward Therapeutics, Inc. (US) | 2025-10-01 | — | — | EP | disclosed |
| US-12384808-B2 | Modulators of TNF-α activity | FORWARD THERAPEUTICS, INC. (US) | 2025-08-12 | — | — | US | disclosed |
| CN-120192780-A | Fluorine-containing benzene alkyne liquid crystal compound, preparation method and composition thereof | 西安近代化学研究所 | 2025-06-24 | — | — | CN | disclosed |
| EP-1237845-B1 | AMINOBENZOPHENONES AS INHIBITORS OF IL-1BETA AND TNF-ALPHA | LEO PHARMA AS (DK) | 2007-05-23 | — | — | EP | disclosed |
| US-7125589-B1 | Liquid crystal compound having hydrogen as a terminal group, composition comprising the compound, and liquid crystal display element comprising the composition | CHISSO CORPORATION (JP) | 2006-10-24 | — | — | US | disclosed |
| EP-1352886-B1 | Liquid crystal compound having hydrogen as a terminal group, composition comprising the compound, and liquid crystal display element comprising the composition | CHISSO CORP (JP) | 2006-03-22 | — | — | EP | disclosed |
| EP-1352886-A1 | Liquid crystal compound having hydrogen as a terminal group, composition comprising the compound, and liquid crystal display element comprising the composition | CHISSO CORPORATION (JP) | 2003-10-15 | — | — | EP | disclosed |
| US-6541670-B2 | Antiinflammatory agents | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) | 2003-04-01 | — | — | US | disclosed |
| US-20030013770-A1 | Aminobenzophenones as inhibitors of il 1b and tnf | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) | 2003-01-16 | — | — | US | disclosed |
| EP-1237845-A1 | AMINOBENZOPHENONES AS INHIBITORS OF IL-1BETA AND TNF-ALPHA | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (LOVENS KEMISKE FABRIK PRODUKTIONSAKTIESELSKAB) (DK) | 2002-09-11 | — | — | EP | disclosed |
| EP-0530338-B1 | ANISOTROPIC ORGANIC COMPOUNDS | QINETIQ LTD (GB) | 2002-05-02 | — | — | EP | disclosed |
| WO-2001042189-A1 | AMINOBENZOPHENONES AS INHIBITORS OF IL-1β AND TNF-$g(a) | LEO PHARMA A/S (DK) | 2001-06-14 | — | — | WO | disclosed |
| US-5888421-A | LIQUID CRYSTALS | THE SECRETARY OF STATE FOR DEFENCE IN HER BRITANNIC MAJESTY'S GOVERNMENT OF THE UNITED KINGDOM OF GREAT BRITAIN AND NORTHERN IRELAND (GB) | 1999-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12590091-B2 | 1H-pyrrolo[3,2-C]pyridine and 1H-pyrrolo[2,3-C]pyridine derivatives as TLR9 inhibitors for the treatment of fibrosis | TLR9, TLR1, TLR3 | KDM1A 884/4885KDM1B 671/4885KCNH2 1420/4885 |
| US-20260124309-A1 | STAT6 DEGRADERS AND USES THEREOF | STAT6, NCOR2, NCOR1 | KDM1A 1642/4885KDM1B 982/4885KCNH2 4066/4885 |
| US-20030013770-A1 | Aminobenzophenones as inhibitors of il 1b and tnf | IL1B, IL1A, IL6 | KDM1A 919/4885KDM1B 878/4885KCNH2 435/4885 |
| US-12384808-B2 | Modulators of TNF-α activity | TNF, NFKBIA, TNFRSF1A | KDM1A 3878/4885KDM1B 4493/4885KCNH2 4764/4885 |
| US-20250333429-A1 | MODULATORS OF TNF-ALPHA ACTIVITY | TNF, NFKBIA, TNFRSF1A | KDM1A 4193/4885KDM1B 4613/4885KCNH2 4777/4885 |
| US-20260048035-A1 | MODULATORS OF TNF-ALPHA ACTIVITY | TNF, TNFRSF1A, CD40 | KDM1A 3144/4885KDM1B 3607/4885KCNH2 2969/4885 |
| US-20250345310-A1 | MODULATORS OF TNF-ALPHA ACTIVITY | TNF, TNFRSF1A, NFKBIA | KDM1A 4378/4885KDM1B 4699/4885KCNH2 4767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.